Compugen (NASDAQ:CGEN) Share Price Crosses Above Two Hundred Day Moving Average – What’s Next?

Compugen Ltd. (NASDAQ:CGEN) shares crossed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $2.14 and traded as high as $2.19. Compugen shares last traded at $2.14, with a volume of 286,183 shares.

Wall Street Analysts Forecast Growth

CGEN has been the topic of several recent analyst reports. Leerink Partners decreased their target price on shares of Compugen from $13.00 to $5.00 and set an “outperform” rating on the stock in a report on Thursday, May 21st. Wall Street Zen downgraded shares of Compugen from a “buy” rating to a “hold” rating in a report on Saturday, May 23rd. Lake Street Capital assumed coverage on shares of Compugen in a research report on Tuesday, April 7th. They set a “buy” rating and a $6.00 price target on the stock. Truist Financial raised shares of Compugen to a “strong-buy” rating in a research note on Wednesday, March 25th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Compugen in a research report on Monday, April 20th. One investment analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $5.00.

Compugen Trading Down 0.9%

The firm has a 50-day moving average of $2.49 and a two-hundred day moving average of $2.14. The firm has a market capitalization of $202.34 million, a P/E ratio of 5.78 and a beta of 2.74.

Compugen (NASDAQ:CGEN) last released its earnings results on Monday, May 18th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.01). The business had revenue of $2.18 million during the quarter, compared to the consensus estimate of $1.57 million. Compugen had a net margin of 47.97% and a return on equity of 47.72%. On average, sell-side analysts anticipate that Compugen Ltd. will post -0.28 EPS for the current fiscal year.

Institutional Investors Weigh In On Compugen

A number of hedge funds have recently made changes to their positions in CGEN. Bank Hapoalim BM bought a new stake in shares of Compugen during the 4th quarter valued at approximately $37,000. Security National Bank of Sioux City Iowa IA bought a new position in Compugen in the 4th quarter valued at approximately $38,000. Calamos Advisors LLC bought a new position in Compugen in the 1st quarter valued at approximately $63,000. Franklin Resources Inc. acquired a new stake in Compugen in the second quarter valued at approximately $56,000. Finally, Hillsdale Investment Management Inc. acquired a new stake in Compugen in the first quarter valued at approximately $68,000. 12.22% of the stock is currently owned by institutional investors and hedge funds.

Compugen Company Profile

Compugen Ltd. (NASDAQ: CGEN) is a clinical-stage therapeutic discovery company that leverages proprietary computational discovery platforms to identify novel immuno-oncology targets and biomarkers. The company combines large-scale biological datasets with machine learning algorithms to generate and validate new therapeutic and diagnostic candidates. Founded in 1993 and headquartered in Tel Aviv, Israel, Compugen also maintains a presence in the United States to support its clinical development and commercial collaborations.

Compugen’s predictive discovery engine scans complex biological systems in silico to reveal previously unrecognized pathways and immune checkpoints involved in cancer progression.